Broadly neutralizing antibodies display potential for prevention of HIV-1 infection of mucosal tissue superior to that of nonneutralizing antibodies

Journal of Virology

Volumn 91, Issue 1, 2017, Pages

  Cheeseman, Hannah M ^a   Olejniczak, Natalia J ^a   Rogers, Paul M ^a   Evans, Abbey B ^a   King, Deborah F L ^a   Ziprin, Paul ^b   Liao, Hua Xin ^c   Haynes, Barton F ^c   Shattock, Robin J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HIV vaccines; Human immunodeficiency virus; Mucosal immunity; Neutralizing antibodies; Nonneutralizing antibodies

Indexed keywords

BROADLY NEUTRALIZING ANTIBODY; CD4 ANTIGEN; FC RECEPTOR; GLYCAN DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MEMBRANE PROXIMAL EXTERNAL REGION BROADLY NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY; NONNEUTRALIZING ANTIBODY; OUTER DOMAIN GLYCAN BROADLY NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING SITE; CELL ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; INFECTION PREVENTION; LYMPHOCYTE COUNT; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CYTOLOGY; DENDRITIC CELL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HELA CELL LINE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MACROPHAGE; MALE; MONONUCLEAR CELL; MUCOSA; MUCOSAL IMMUNITY; PENIS; RECTUM; TISSUE CULTURE TECHNIQUE; UTERINE CERVIX; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CERVIX UTERI; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; HELA CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MALE; MODELS, BIOLOGICAL; MUCOUS MEMBRANE; PENIS; RECEPTORS, IGG; RECTUM; TISSUE CULTURE TECHNIQUES;

EID: 85008145370     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01762-16     Document Type: Article

References (68)

1. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24:739-769. https://doi.org/10.1146/annurev.immunol.24.021605.090557.
2. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. 2014 Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28:163-169. https://doi.org/10.1097/QAD.0000000000000106.
3. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC. 2013. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153:126-138. https://doi.org/10.1016/j.cell.2013.03.018.
4. Alter G, Moody MA. 2010. The humoral response to HIV-1: new insights, renewed focus. J Infect Dis 202(Suppl 2):S315-S322. https://doi.org/10.1086/655654.
5. Richard J, Veillette M, Ding S, Zoubchenok D, Alsahafi N, Coutu M, Brassard N, Park J, Courter JR, Melillo B, Smith AB, III, Shaw GM, Hahn BH, Sodroski J, Kaufmann DE, Finzi A. 2016. Small CD4 mimetics prevent HIV-1 uninfected bystander CD4+ T cell killing mediated by antibodydependent cell-mediated cytotoxicity. EBioMedicine 3:122-134. https://doi.org/10.1016/j.ebiom.2015.12.004.
6. Stieh DJ, King DF, Klein K, Aldon Y, McKay PF, Shattock RJ. 2015. Discrete partitioning of HIV-1 Env forms revealed by viral capture. Retrovirology 12:81. https://doi.org/10.1186/s12977-015-0207-z.
7. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. 2007 Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104. https://doi.org/10.1038/nature06106.
8. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K, Mankoff Z, Schmidt SD, Lifson JD, Mascola JR, Nussenzweig MC, Martin MA. 2016. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533:105-109. https://doi.org/10.1038/nature17677.
9. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-2220. https://doi.org/10.1056/NEJMoa0908492.
10. Veillette M, Richard J, Pazgier M, Lewis GK, Parsons MS, Finzi A. 2016. Role of HIV-1 envelope glycoproteins conformation and accessory proteins on ADCC responses. Curr HIV Res 14:9-23.
11. von Bredow B, Arias JF, Heyer LN, Moldt B, Le K, Robinson JE, Zolla-Pazner S, Burton DR, Evans DT. 2016. Comparison of antibodydependent cell-mediated cytotoxicity and virus neutralization by HIV-1 Env-specific monoclonal antibodies. J Virol 90:6127-6139. https://doi.org/10.1128/JVI.00347-16.
12. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275-1286. https://doi.org/10.1056/NEJMoa1113425.
13. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 110: 9019-9024. https://doi.org/10.1073/pnas.1301456110.
14. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD. 2014. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 6:228ra239.
15. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF. 2012. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86:11521-11532. https://doi.org/10.1128/JVI.01023-12.
16. Forthal DN, Landucci G, Daar ES. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 75:6953-6961. https://doi.org/10.1128/JVI.75.15.6953-6961.2001.
17. Sips M, Krykbaeva M, Diefenbach TJ, Ghebremichael M, Bowman BA, Dugast AS, Boesch AW, Streeck H, Kwon DS, Ackerman ME, Suscovich TJ, Brouckaert P, Schacker TW, Alter G. 2016. Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal Immunol https://doi.org/10.1038/mi.2016.12.
18. Wu L. 2008. Biology of HIV mucosal transmission. Curr Opin HIV AIDS 3:534-540. https://doi.org/10.1097/COH.0b013e32830634c6.
19. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ. 2007. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26: 257-270. https://doi.org/10.1016/j.immuni.2007.01.007.
20. Harman AN, Kim M, Nasr N, Sandgren KJ, Cameron PU. 2013. Tissue dendritic cells as portals for HIV entry. Rev Med Virol 23:319-333. https://doi.org/10.1002/rmv.1753.
21. Rinaldo CR. 2013. HIV-1 trans infection of CD4+ T cells by professional antigen presenting cells. Scientifica 2013:30.
22. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, Dable J, Stossel H, Romani N, Piatak M, Jr, Lifson JD, Pope M, Cunningham AL. 2004. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 103:2170-2179. https://doi.org/10.1182/blood-2003-09-3129.
23. Peters PJ, Gonzalez-Perez MP, Musich T, Moore Simas TA, Lin R, Morse AN, Shattock RJ, Derdeyn CA, Clapham PR. 2015. Infection of ectocervical tissue and universal targeting of T-cells mediated by primary nonmacrophage-tropic and highly macrophage-tropic HIV-1 R5 envelopes. Retrovirology 12:48. https://doi.org/10.1186/s12977-015-0176-2.
24. King DF, Siddiqui AA, Buffa V, Fischetti L, Gao Y, Stieh D, McKay PF, Rogers P, Ochsenbauer C, Kappes JC, Arts EJ, Shattock RJ. 2013. Mucosal tissue tropism and dissemination of HIV-1 subtype B acute envelopeexpressing chimeric virus. J Virol 87:890-899. https://doi.org/10.1128/JVI.02216-12.
25. Stieh DJ, Matias E, Xu H, Fought AJ, Blanchard JL, Marx PA, Veazey RS, Hope TJ. 2016. Th17 cells are preferentially infected very early after vaginal transmission of SIV in macaques. Cell Host Microbe 19:529-540. https://doi.org/10.1016/j.chom.2016.03.005.
26. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF. 2011. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 85: 7029-7036. https://doi.org/10.1128/JVI.00171-11.
27. Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ, Le Grand R. 2014. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 7:46-56. https://doi.org/10.1038/mi.2013.23.
28. Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF. 2015 Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog 11:e1005042. https://doi.org/10.1371/journal.ppat.1005042.
29. Liu P, Williams LD, Shen X, Bonsignori M, Vandergrift NA, Overman RG, Moody MA, Liao H-X, Stieh DJ, McCotter KL, French AL, Hope TJ, Shattock R, Haynes BF, Tomaras GD. 2014. Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. J Virol 88:5165-5170. https://doi.org/10.1128/JVI.03765-13.
30. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH. 2012 Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206: 431-441. https://doi.org/10.1093/infdis/jis367.
31. Ding S, Veillette M, Coutu M, Prevost J, Scharf L, Bjorkman PJ, Ferrari G, Robinson JE, Sturzel C, Hahn BH, Sauter D, Kirchhoff F, Lewis GK, Pazgier M, Finzi A. 2016. A highly conserved residue of the HIV-1 gp120 inner domain is important for antibody-dependent cellular cytotoxicity responses mediated by anti-cluster A antibodies. J Virol 90:2127-2134. https://doi.org/10.1128/JVI.02779-15.
32. Pollara J, Bonsignori M, Moody MA, Pazgier M, Haynes BF, Ferrari G. 2013 Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res 11: 378-387. https://doi.org/10.2174/1570162X113116660059.
33. Cheeseman HM, Carias AM, Evans AB, Olejniczak NJ, Ziprin P, King DF, Hope TJ, Shattock RJ. 2016. Expression profile of human Fc receptors in mucosal tissue: implications for antibody-dependent cellular effector functions targeting HIV-1 transmission. PLoS One 11:e0154656. https://doi.org/10.1371/journal.pone.0154656.
34. Klein K, Veazey RS, Warrier R, Hraber P, Doyle-Meyers LA, Buffa V, Liao HX, Haynes BF, Shaw GM, Shattock RJ. 2013. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. J Virol 87:11604-11616. https://doi.org/10.1128/JVI.01361-13.
35. Georgiev IS, Gordon Joyce M, Zhou T, Kwong PD. 2013. Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Curr Opin HIV AIDS 8:382-392. https://doi.org/10.1097/COH.0b013e328363a90e.
36. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, Todd JP, Letvin NL, Huang J, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ. 2014. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 6:243ra288.
37. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD. 2013. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 20:804-813. https://doi.org/10.1038/nsmb.2600.
38. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. https://doi.org/10.1126/science.1178746.
39. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Pena AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP. 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9:e1003618. https://doi.org/10.1371/journal.ppat.1003618.
40. Scott YM, Park SY, Dezzutti CS. 2016. Broadly neutralizing anti-HIV antibodies prevent HIV infection of mucosal tissue ex vivo. Antimicrob Agents Chemother 60:904-912. https://doi.org/10.1128/AAC.02097-15.
41. McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW, Schuitemaker H, Poignard P, Wrin T, Burton DR. 2015. Incomplete neutralization and deviation from sigmoidal neutralization curves for HIV broadly neutralizing monoclonal antibodies. PLoS Pathog 11:e1005110. https://doi.org/10.1371/journal.ppat.1005110.
42. Huskens D, Van Laethem K, Vermeire K, Balzarini J, Schols D. 2007. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 360:294-304. https://doi.org/10.1016/j.virol.2006.10.027.
43. Platt EJ, Gomes MM, Kabat D. 2012. Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry. Proc Natl Acad Sci U S A 109:7829-7834. https://doi.org/10.1073/pnas.1109728109.
44. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:e1000433. https://doi.org/10.1371/journal.ppat.1000433.
45. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:1302-1313.
46. Wolbank S, Kunert R, Stiegler G, Katinger H. 2003. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol 77:4095-4103. https://doi.org/10.1128/JVI.77.7.4095-4103.2003.
47. Tudor D, Yu H, Maupetit J, Drillet AS, Bouceba T, Schwartz-Cornil I, Lopalco L, Tuffery P, Bomsel M. 2012. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci U S A 109:12680-12685. https://doi.org/10.1073/pnas.1200024109.
48. Perez LG, Zolla-Pazner S, Montefiori DC. 2013. Antibody-dependent, FcgammaRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. J Virol 87:5287-5290. https://doi.org/10.1128/JVI.00278-13.
49. Malbec M, Porrot F, Rua R, Horwitz J, Klein F, Halper-Stromberg A, Scheid JF, Eden C, Mouquet H, Nussenzweig MC, Schwartz O. 2013. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med 210:2813-2821. https://doi.org/10.1084/jem.20131244.
50. Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, Kepler TB, Alam SM, Liao H-X, Cain DW, Spicer L, VandeBerg JL, Haynes BF, Kelsoe G. 2013. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 210:241-256. https://doi.org/10.1084/jem.20121977.
51. Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G. 2014. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 88:7715-7726. https://doi.org/10.1128/JVI.00156-14.
52. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. 2014. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol 14:94-108. https://doi.org/10.1038/nri3582.
53. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin AM, Moog C. 2006. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 80:6177-6181. https://doi.org/10.1128/JVI.02625-05.
54. Gummuluru S, Pina Ramirez NG, Akiyama H. 2014. CD169-dependent cell-associated HIV-1 transmission: a driver of virus dissemination. J Infect Dis 210(Suppl 3):S641-S647.
55. Su B, Xu K, Lederle A, Peressin M, Biedma ME, Laumond G, Schmidt S, Decoville T, Proust A, Lambotin M, Holl V, Moog C. 2012. Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes. Blood 120:3708-3717. https://doi.org/10.1182/blood-2012-03-418913.
56. Dugast AS, Chan Y, Hoffner M, Licht A, Nkolola J, Li H, Streeck H, Suscovich TJ, Ghebremichael M, Ackerman ME, Barouch DH, Alter G. 2014 Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One 9:e97229. https://doi.org/10.1371/journal.pone.0097229.
57. Nakane T, Nomura T, Shi S, Nakamura M, Naruse TK, Kimura A, Matano T, Yamamoto H. 2013. Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques. PLoS One 8:e73453. https://doi.org/10.1371/journal.pone.0073453.
58. Moldt B, Le KM, Carnathan DG, Whitney JB, Schultz N, Lewis MG, Borducchi EN, Smith KM, Mackel JJ, Sweat SL, Hodges AP, Godzik A, Parren PW, Silvestri G, Barouch DH, Burton DR. 2016. Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. AIDS 30: 1543-1551. https://doi.org/10.1097/QAD.0000000000001102.
59. Shen R, Meng G, Ochsenbauer C, Clapham PR, Grams J, Novak L, Kappes JC, Smythies LE, Smith PD. 2011. Stromal down-regulation of macrophage CD4/CCR5 expression and NF-kappaB activation mediates HIV-1 non-permissiveness in intestinal macrophages. PLoS Pathog 7:e1002060. https://doi.org/10.1371/journal.ppat.1002060.
60. Merbah M, Arakelyan A, Edmonds T, Ochsenbauer C, Kappes JC, Shattock RJ, Grivel JC, Margolis LB. 2012. HIV-1 expressing the envelopes of transmitted/founder or control/reference viruses have similar infection patterns of CD4 T-cells in human cervical tissue ex vivo. PLoS One 7:e50839. https://doi.org/10.1371/journal.pone.0050839.
61. Tay MZ, Liu P, Williams LD, McRaven MD, Sawant S, Gurley TC, Xu TT, Dennison SM, Liao HX, Chenine AL, Alam SM, Moody MA, Hope TJ, Haynes BF, Tomaras GD. 2016. Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses. PLoS Pathog 12:e1005817. https://doi.org/10.1371/journal.ppat.1005817.
62. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725. https://doi.org/10.1182/blood-2008-09-179754.
63. Haase AT. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:217-223. https://doi.org/10.1038/nature08757.
64. Zhang R, Alam SM, Yu JS, Scearce R, Lockwood B, Hwang KK, Parks R, Permar S, Brandtzaeg P, Haynes BF, Liao HX. 2016. Novel monoclonal antibodies for studies of human and rhesus macaque secretory component and human J-chain. Monoclon Antib Immunodiagn Immunother 35:217-226. https://doi.org/10.1089/mab.2016.0014.
65. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591-6604. https://doi.org/10.1074/jbc.M009483200.
66. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 108:14216-14221. https://doi.org/10.1073/pnas.1111497108.
67. Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R. 2005. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 79:11179-11186. https://doi.org/10.1128/JVI.79.17.11179-11186.2005.
68. Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Pope M, Shattock RJ. 2004. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 199: 1065-1075. https://doi.org/10.1084/jem.20022212.